Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $77.9 million.

  • SAB Biotherapeutics' Shares Outstanding (Diluted Average) rose 74092.93% to $77.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 74092.93%. This contributed to the annual value of $9.3 million for FY2024, which is 6774.32% up from last year.
  • SAB Biotherapeutics' Shares Outstanding (Diluted Average) amounted to $77.9 million in Q3 2025, which was up 74092.93% from $9.3 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Shares Outstanding (Diluted Average) ranged from a high of $77.9 million in Q3 2025 and a low of $4.4 million during Q4 2022
  • In the last 5 years, SAB Biotherapeutics' Shares Outstanding (Diluted Average) had a median value of $9.3 million in 2024 and averaged $18.5 million.
  • In the last 5 years, SAB Biotherapeutics' Shares Outstanding (Diluted Average) plummeted by 8828.73% in 2023 and then soared by 74092.93% in 2025.
  • SAB Biotherapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $26.0 million in 2021, then plummeted by 83.24% to $4.4 million in 2022, then grew by 26.86% to $5.5 million in 2023, then skyrocketed by 67.74% to $9.3 million in 2024, then soared by 740.68% to $77.9 million in 2025.
  • Its last three reported values are $77.9 million in Q3 2025, $9.3 million for Q2 2025, and $9.3 million during Q1 2025.